Taysha Gene Therapies, Inc. TSHA

TSHA Company Overview

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). The company operates within the biotechnology and genetic medicine industries, with an emphasis on rare neurodevelopmental and neurodegenerative disorders that currently have limited or no approved treatment options. Taysha’s primary value drivers are its clinical development programs, intellectual property related to gene therapy delivery and manufacturing, and strategic collaborations supporting translational research and commercialization readiness.

The company was founded in 2020 and originated from research and technology collaborations associated with The University of Texas Southwestern Medical Center. Taysha initially pursued a broad portfolio of neurological gene therapy programs before restructuring to prioritize lead assets with clearer clinical and regulatory pathways. Its strategy evolved toward concentrating capital and operational resources on late-preclinical and clinical-stage CNS programs, particularly Rett syndrome and related neurological conditions, while leveraging AAV technology platforms and manufacturing partnerships to support long-term development.